Sowell Financial Services LLC Has $12.32 Million Stock Holdings in AbbVie Inc. $ABBV

Sowell Financial Services LLC trimmed its position in AbbVie Inc. (NYSE:ABBV) by 14.1% during the third quarter, Holdings Channel reports. The firm owned 53,225 shares of the company’s stock after selling 8,716 shares during the quarter. Sowell Financial Services LLC’s holdings in AbbVie were worth $12,324,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Brighton Jones LLC raised its stake in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its position in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Titleist Asset Management LLC increased its holdings in shares of AbbVie by 13.9% in the first quarter. Titleist Asset Management LLC now owns 1,730 shares of the company’s stock valued at $362,000 after purchasing an additional 211 shares during the last quarter. Saudi Central Bank bought a new position in shares of AbbVie in the first quarter valued at about $146,000. Finally, Calton & Associates Inc. lifted its stake in shares of AbbVie by 73.4% during the 1st quarter. Calton & Associates Inc. now owns 6,176 shares of the company’s stock worth $1,294,000 after buying an additional 2,615 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.1%

Shares of NYSE:ABBV opened at $230.07 on Monday. The business’s 50 day simple moving average is $226.73 and its 200 day simple moving average is $212.72. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The company has a market capitalization of $406.63 billion, a P/E ratio of 174.30, a P/E/G ratio of 1.31 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the firm posted $3.00 EPS. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ABBV. JPMorgan Chase & Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Piper Sandler restated an “overweight” rating and set a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Finally, Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $245.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.